206 related articles for article (PubMed ID: 22974232)
1. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
Nickoloff BJ; Vande Woude G
Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
[No Abstract] [Full Text] [Related]
2. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
3. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
4. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
5. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
[TBL] [Abstract][Full Text] [Related]
6. BRAF in melanoma: current strategies and future directions.
Salama AK; Flaherty KT
Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.
Lai F; Jin L; Gallagher S; Mijatov B; Zhang XD; Hersey P
Adv Pharmacol; 2012; 65():27-43. PubMed ID: 22959022
[TBL] [Abstract][Full Text] [Related]
8. Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms.
Li QS; Shen BN; Xu HJ; Ruan BF
Anticancer Agents Med Chem; 2020; 20(12):1415-1430. PubMed ID: 32321411
[TBL] [Abstract][Full Text] [Related]
9. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
Haluska F; Pemberton T; Ibrahim N; Kalinsky K
Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
[TBL] [Abstract][Full Text] [Related]
10. On or off target: mutations, models, and predictions.
Garraway LA; Hahn WC
Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617
[TBL] [Abstract][Full Text] [Related]
11. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
[TBL] [Abstract][Full Text] [Related]
12. The new arms race against melanoma.
Lejeune FJ
Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449
[No Abstract] [Full Text] [Related]
13. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
[TBL] [Abstract][Full Text] [Related]
14. The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
Filitis DC; Rauh J; Mahalingam M
Melanoma Res; 2015 Dec; 25(6):470-8. PubMed ID: 26317169
[TBL] [Abstract][Full Text] [Related]
15. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
Verduzco D; Flaherty KT; Smalley KS
Exp Dermatol; 2015 Sep; 24(9):657-8. PubMed ID: 26010519
[No Abstract] [Full Text] [Related]
16. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
17. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
18. Microenvironment-mediated resistance to anticancer therapies.
Olson OC; Joyce JA
Cell Res; 2013 Feb; 23(2):179-81. PubMed ID: 22945358
[TBL] [Abstract][Full Text] [Related]
19. Towards a unified model of RAF inhibitor resistance.
Solit DB; Rosen N
Cancer Discov; 2014 Jan; 4(1):27-30. PubMed ID: 24402945
[TBL] [Abstract][Full Text] [Related]
20. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.
Lo RS; Shi H
Methods Mol Biol; 2014; 1102():163-74. PubMed ID: 24258979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
